AMGEN Breakthrough Innovation: The First and Only Bispecific T-cell Engager (BiTE®) Therapy for 2L+ Extensive-Stage Small Cell Lung Cancer (ES-SCLC) – Aug 13th
Loading Map....
AMGEN Cordially Invites You to Attend a Program Titled Breakthrough Innovation: The First and Only Bispecific T-cell Engager (BiTE®) Therapy for 2L+ Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Speaker: Siamak Saadat, MD
Where: Alexander’s Steakhouse (The Great Room)
19379 Steven’s Creek Boulevard
Cupertino, CA 95014
(408) 446-2222
When: Wednesday, August 13, 2025, 6:00 PM Pacific
Please RSVP to: Molly Daste
Phone: (831) 238-7805
E-mail: mdaste@amgen.com